According to the “Tumor Marker Utility Grading System” guidelines [236,237], the next step would be to launch an appropriate prospective study where the benefit of using plasma YKL-40 levels in the clinical decision-making process is assessed. The gene discussed is CHI3L1; the disease is neoplasm.